Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex
Samantha H. Rosen, Kian Asanad · 2025
Read Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex by Samantha H. Rosen, Kian Asanad (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12821475.txt.
Description
Jeremy Rosen and Samuel Asanad published a review in 2025 of newer oral testosterone therapies for symptomatic male hypogonadism, a condition in which the body makes too little of the hormone. Traditional oral forms damaged the liver and were poorly absorbed, so patients reluctantly turned to clinic injections or to gels and patches applied daily.
The review compares three newer oral products, all built on one hormone compound absorbed into the lymphatic system instead of the liver. In clinical trials, all three restored testosterone to the normal range in most patients. The three share the hormone's class-wide risks: high blood pressure, excess red blood cells, and changes in cholesterol levels. They differ in dosing regimens, in how doses are titrated, and in insurance coverage. One product offers flexible dose titration and direct-pay access. One comes at a fixed dose. A third is titratable and supported by established data.
Catalog record
| CREATOR | Samantha H. Rosen, Kian Asanad |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |